Abstract
Alzheimer’s Disease (AD) has been one of the most prevalent neurodegenerative disorders that majorly affect patients older than 65 years old. The treatment of the disease costs over 1% of the global GDP [1], yet not many new drugs have been developed which can effectively treat AD based on its pathological characteristics. The major challenge in treating brain disorders such as AD is the Blood-Brain Barrier (BBB) which refrains most of the drug molecules from entering the brain. Through reviewing multiple papers from PubMed Central®(PMC), which is an archive of biomedical and life sciences journal literature at the U.S. National Institutes of Health’s National Library of Medicine (NIH/NLM), three promising drug delivery pathways have been investigated regarding their capabilities and effectivenesses of transporting drug molecules into the brain, which are inorganic nanoparticles, multifunctional liposomes, and transdermal delivery system. In this paper, brief introductions regarding each delivery pathway were offered, and specific experiment that supported the delivery method was presented. The advantages, as well as drawbacks of each type of delivery pathway, were also discussed in this paper.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
